Pfizer Plans To Evaluate Third Shot For Its COVID-19 Vaccine In Kids Below 5 Years

Following routine review by the external independent Data Monitoring Committee (DMC), BioNTech SE BNTXPfizer Inc PFE will amend the clinical study evaluating their COVID-19 vaccine in children six months to under five years of age. 

  • The study will now include evaluating a third dose of 3 µg at least two months after the second dose of the two-dose series to provide high levels of protection in this young age group.
  • While the study is ongoing and remains blinded, a pre-specified immunogenicity analysis was conducted on a subset of the study population one month following the second dose. 
  • Related: Pfizer Submits Application For Approval Of COVID-19 Shot For Adolescents Aged 12 To 15 Years.
  • Compared to the 16 - 25 years old population in which high efficacy was demonstrated, non-inferiority was met for the 6 - 24 months old but not for the 2 - 5 years population. 
  • No safety concerns were identified, and the 3 µg dose demonstrated a favorable safety profile.
  • Pfizer previously said it might apply for a EUA for this youngest population by the end of December or early 2022.
  • But now, if the three-dose study proves successful, Pfizer and BioNTech expect to submit data in 1H of 2022.
  • Pfizer and BioNTech are also shifting to a three-dose regimen for all ages.
  • The companies plan to evaluate a third dose of the 10 µg formulation in children five to under 12 years. 
  • Additionally, the companies have initiated a low dose sub-study of a third dose of 10 µg or 30 µg in approximately 600 adolescents aged 12 - 17 years to assess safety and immunogenicity.
  • Price Action: PFE shares are down 2.08% at $59.98, BNTX stock is up 0.69% at $285.58 during the market session on the last check Friday.
  • Photo by x3 from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!